Vertex Pharmaceuticals

VRTXintermediary

Vertex Pharmaceuticals dominates the cystic fibrosis market with Trikafta and is expanding into gene editing (Casgevy for sickle cell), non-opioid pain (suzetrigine), and kidney disease. Its CF franchise generates massive cash flow to fund pipeline diversification.

⇄ Compare

產品與營收

產品營收佔比

營收結構 ($11.2B)

靜態數據（加載即時財務…）

Cystic Fibrosis (Trikafta) (78%)

Gene Therapy (Casgevy) (8%)

Other Products & Collaborations (14%)

業務部門構成與主要客戶

產品詳情

Trikafta / Kaftrio65%

Triple-combination CFTR modulator for cystic fibrosis — standard of care

Casgevy (exa-cel)8%

CRISPR-based gene therapy for sickle cell disease and beta-thalassemia

Pain Pipeline (VX-548, suzetrigine)10%

Non-opioid NaV1.8 pain inhibitor for acute and neuropathic pain

供應鏈關係

競爭對手

Eli Lilly and Company

Pain therapeutics pipeline

影響: Competing in non-opioid pain

Regeneron Pharmaceuticals

Gene editing and rare disease

影響: Competing in genetic medicine

Pfizer Inc.

Gene therapy and rare disease

影響: Limited overlap

宏觀與市場背景

제약 / 바이오行業新聞

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

近期催化劑

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

AI 分析

點擊「取得 AI 分析」以獲得 Vertex Pharmaceuticals 的 AI 供應鏈分析。

企業資訊

總部

Boston, Massachusetts, USA

成立時間

1989

員工人數

10,400+

官網

vrtx.com

行業概況 — 제약 / 바이오

行業新聞